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Abstract 
Aim: Gluten-free diet has shown promising effects in preventing type 1 diabetes (T1D) in animals as well as benefi-
cial effects on the immune system. Gluten-free diet at diabetes onset may alter the natural course and outcome of 
autoimmune diseases such as T1D.
Methods: In a 12-month study, 15 children newly diagnosed with T1D were instructed to follow a gluten-free 
diet. Questionnaires were used to evaluate adherence to the gluten-free diet. Partial remission (PR) was defined by 
insulin dose-adjusted A1c (IDAA1c) ≤9 or stimulated C-peptide (SCP) >300 pmol/L measured 90 min after a liquid 
mixed meal at the inclusion, six and 12 months after onset. The intervention group was compared with two previous 
cohorts. Linear mixed models were used to estimate differences between cohorts.
Results: After 6 months, more children on a gluten-free diet tended to have SCP values above 300 pmol/L compared 
to the European cohort (p = 0.08). The adherence to a gluten-free diet decreased during the 12-month study period. 
After 1 year there was no difference in SCP levels or percentage in remission according to SCP (p > 0.1). Three times 
as many children were still in PR based on IDAA1c (p < 0.05). Twelve months after onset HbA1c were 21 % lower and 
IDAA1c >1 unit lower in the cohort on a gluten-free diet compared to the two previous cohorts (p < 0.001).
Conclusion: Gluten-free diet is feasible in highly motivated families and is associated with a significantly better out-
come as assessed by HbA1c and IDAA1c. This finding needs confirmation in a randomized trial including screening for 
quality of life. (Clinicaltrials.gov number NCT02284815).
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Background
Maintained endogenous insulin production in patients 
with type 1 diabetes (T1D) is associated with better met-
abolic control and a lower prevalence of adverse events, 
including hypoglycemia, ketoacidosis and micro-vascu-
lar complication (Sjöberg et  al. 1987; Steffes et  al. 2003; 
Madsbad et  al. 1986; Lachin et  al. 2014; Madsbad et  al. 
1979). C-peptide is used as a measure of endogenous 
insulin production and is tested either fasting or after 
mixed meal stimulation (Palmer et al. 2004; Besser et al. 
2013; Garcia-Webb et al. 1982; Greenbaum et al. 2008).
Shortly after their diagnoses, most patients with T1D 
experience an increase in endogenous insulin release, 
which peaks approximately 3 months after onset. This is 
partly caused by beta-cell rest and by a reduction in the 
immune inflammatory conditions in the islets (Schloot 
et al. 2007; Aly and Gottlieb 2009). The remission or hon-
eymoon phase is the period with sufficient endogenous 
insulin release to cover approximately 50 % of the insulin 
needed.
Many attempts have been made to prolong the remis-
sion phase through insulin prophylaxis to induce beta-
cell rest, immune-modulating therapy such as anti-CD3 
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or anti-CD 20 or vaccines with GAD alumn, all without 
convincing effects (Ludvigsson 2007; Brown and Rother 
2008; Keymeulen et al. 2010; Pescovitz et al. 2014; Lud-
vigsson et al. 2012). An alternative intervention is a glu-
ten-free diet. This is motivated by animal studies where 
gluten has been shown to affect gut permeability, pro-
inflammation, beta cells, natural killer (NK) cells and gut 
microbiota (Drago et  al. 2006; Ejsing-Duun et  al. 2008; 
Antvorskov et  al. 2013; Dall et  al. 2013; Marietta et  al. 
2013; Larsen et al. 2014).
Epidemiological evidence suggests that a gluten-free 
diet may have a positive effect in the protection against 
T1D in humans with coeliac disease. For instance, one 
study observed protection against the development 
of T1D in celiac patients adhering to gluten-free diet 
(Cosnes et al. 2008). Evidence, however, is conflicting as 
other studies found no protection (Viljamaa et al. 2005). 
The importance of gluten in T1D is highlighted by cohort 
studies finding that early introduction of gluten in the 
diet (before 3 months of age) increases the prevalence of 
diabetes autoantibodies fourfold in high-risk individu-
als (Norris et  al. 2003; Ziegler et  al. 2003). Two smaller 
studies have evaluated the effect of a 6-month or 1-year 
gluten-free diet in high-risk individuals before T1D with 
limited support of an effect on the level of autoantibod-
ies and on the natural course towards diabetes (Hum-
mel et  al. 2002; Pastore et  al. 2003; Fuchtenbusch et  al. 
2004). One of these studies did, however, show signs of 
improved insulin sensitivity as well as insulin secretion 
in the gluten-free diet group compared to the group on a 
normal diet (Pastore et al. 2003).
To our knowledge, the effect of a gluten-free diet at 
the onset of diabetes has not been systematically evalu-
ated and, except for one case report (Sildorf et al. 2012), 
the effect of a gluten-free diet on the duration of PR and 
the SCP decline over time is unknown. The aims of the 
present study were therefore to test the feasibility of a 
gluten-free diet in children with newly diagnosed T1D as 
well as assessing the effect on diabetes outcome.
Methods
This was an observational pilot study including15 chil-
dren ranging from two to 15  years of age with newly 
diagnosed T1D admitted to the Paediatric Department 
at Copenhagen University Hospital, Herlev between 
March 2012 and June 2013. All health care providers 
were informed about the study. Exclusion criteria were 
children with non T1D, below 2  years of age, physi-
cal disabilities, psychiatric diagnosis, social or language 
problems. During this time period 73 patients with 
T1D above 2 years of age were admitted to Herlev with 
newly diagnosed diabetes, two came from another hos-
pital because they had heard about the study. Of the 16 
families included, one never started on a gluten-free 
diet and was excluded entirely. Another family dropped 
out after 6 months due to a loss of interest in continuing 
the gluten-free diet and in one child the boost test was 
not repeated because of immeasurable C-peptide after 
6 months. In the remaining 13 children, who continued 
on the gluten-free diet, the adherence to the diet varied 
(Table 1).
The local ethics committee (Region Hovedstadens 
Videnskabs etiske komité) approved the study (no. H-3-
2011-119) and parents gave their written informed con-
sent. Children with newly diagnosed T1D and their 
parents were invited to participate; those who accepted 
were given advice concerning a gluten-free diet by a 
dietician. They were monitored according to our nor-
mal routine except for a liquid mixed-meal challenge at 
inclusion and at their 6- and 12-month visits to stimulate 
endogenous C-peptide release. The intervention group 
was compared to two paediatric cohorts from Euro-
pean countries (1999–2000) and Denmark (2004–2005), 
including 378 children with new onset T1D described in 
detail elsewhere (Max Andersen et al. 2014a).
Adherence to the gluten-free diet was evaluated by a 
questionnaire, asking the child (if above 11 years of age) 
and the parents about their conception of the importance 
of a gluten-free diet (1–10 scale), as well as their adher-
ence to the diet (‘How sure are you that the gluten-free 
diet is followed at home/outside the home’) (1–100 %).
The PR was defined based on measures of IDAA1c 
(insulin dose-adjusted A1c) and stimulated C-pep-
tide. Patients were in PR if IDAA1c (4*insulin dose/
kg/24 h + HbA1c in  %) ≤9 or C-peptide >300 pmol/L 
(Palmer et al. 2004; Mortensen et al. 2009; Max Andersen 
et al. 2014b).
In the gluten-free cohort, SCP was measured using 
two-site chemiluminescent immunometric assay (Immu-
lite 2500) with a reportable range from 0.03 to 6.6 nmol/L 
and an efficient variance of 20 %. In the European cohort 
and in the Danish cohort the SCP was measured using 
Auto DELFIA C-peptide, PerkinElmer Life and Ana-
lytical Sciences Inc, Turku, Finland, with a sensitivity of 
1  pmol/L and intraassay coefficient of variation below 
6 %.
A liquid mixed-meal Boost™-test (6  mL/kg, max: 
360 mL, Mead Johnson, Evansville, IN, USA; 237 mL = 9 
FL OZ contains 33 g carbohydrate, 15 g protein, and 6 g 
fat, a total of 240 kcal) (Boost High Protein) was used to 
stimulate C-peptide in the European (1, 6 and 12 months 
after onset) and in the gluten-free diet study (inclusion, 
six and 12  months after onset); whereas Boost Original 
(237 mL containing 41 g carbohydrate, 10 g protein and 
4 g fat, 249 kcal) was used to stimulate C-peptide in the 
Danish cohort (one, three, six and 12 months after onset). 
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In all cohorts the test was in the morning after fasting for 
8 h, the morning insulin dose being omitted. The SCP was 
measured 90 min after liquid mixed meals were ingested.
HbA1c was determined using a high-pressure liquid 
chromatographic method (Tosoh Bioscience, South San 
Francisco, CA, USA) working range 23.5–40  mmol/mol 
(4.3–5.8 %).
Blood glucose was measured as capillary values using 
Bayer contour at 0 and 90 min.
Carbohydrates and total energy intake were estimated 
during spring 2013 for all patients independent of the 
date of diagnosis using web-based Dietary Assessment 
Software for Children (WebDASC) developed and vali-
dated as an interactive food record recall method, as 
described in detail elsewhere (Biltoft-Jensen et al. 2013). 
The carbohydrate content in the diet was not a part of 
the protocol but chosen individually by the families. The 
results were compared with dietary intake among healthy 
children participating in the nationally representative 
survey of dietary habits (Pedersen et al. 2010).
Statistics
Descriptive statistics and the non-parametric assessment 
of association based on Spearman’s rank correlation coef-
ficient were used on dietary data. The numbers in PR 
were evaluated using logistic regression. Linear mixed 
models were used for the outcome parameters HbA1C, 
IDAA1c as well as log-transformed C-peptide, allowing 
for repeated measures in the same child by including a 
random child effect. The models included a fixed effect 
of cohort/intervention adjusted for diabetes duration and 
age. Goodness of fit was assessed graphically by means of 
residual plots and quantile plots. Only examination times 
with complete recordings of variables relevant to each of 
these analyses were included in the analyses.
All p values were evaluated at a 5 % significance level. 
Statistical analysis was performed using SAS version 9.3 
(SAS Institute, Cary, NC, USA).
Results
Patients diagnosed in the study period meeting inclusion 
criteria were invited to participate, only those express-
ing interest were approached for further information. Of 
those, approximately 80 % expressed interest in treatment 
prolonging remission, but less than half of the families 
were interested in intervention in the form of a gluten-
free diet early after diagnosis.
Table 1 presents the age, gender and autoantibody sta-
tus as well as the SCP and IDAA1c of the 15 patients in 
the study at inclusion. One patient was autoantibody 
negative for all autoantibodies (ICA, GADA, IA-2A, IAA, 
ZnT8A). The gender, mean age at onset, BMI z-score, and 
Table 1 Age, gender autoantibody status at  onset, SCP (pmol/l) and  IDAA1C, as  well as  the parents’ answers regard-
ing adherence to the gluten-free diet
The lowest value for adherence was chosen if the answers regarding adherence home and outside the home were different, in all cases the adherence outside home 
was lowest
a The pump was not stopped and there were 1.7 units of active insulin in the pump when boost was performed
b 1 unit of insulin was given 1 h prior to boost




















1 F 2 p/p/p/p/p 90 57 <10 <10 9.29 –
2 M 3 p/n/p/p/p 85 269 – 52 8.97 8.63
3 F 3 p/n/p/p/n 100 – 244 109 6.99 10.4
4 M 5 p/n/p/p/p 100 566 308 86 5.99 7.81
5 M 6 p/p/p/p/p 100 384 303 214 6.92 7.86
6 M 8 p/n/p/n/p – 520 427 153a 8.06 9.68
7 M 8 p/p/p/n/p 100 917 211 83 8.72 8.74
8 M 11 p/p/p/p/n 90 543 364 308 9.14 10.7
9 M 12 p/n/p/p/p 100 – 599 137 12.3 13.3
10 M 12 n/n/n/n/n 50 569 298 – 10.0 –
11 F 12 p/n/p/n/n 100 844 818 401 12.9 9.71
12 M 12 p/n/p/p/p 100 781 586b 682 7.03 6.95
13 M 13 p/n/p/p/p 50 503 530 298 8.66 8.97
14 M 13 p/p/p/n/p 100 1360 1770 1210 7.90 7.00
15 F 16 p/p/p/n/n 90 1240 904 245 7.89 11.8
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the corresponding diabetes duration (at inclusion) of the 
three cohorts are presented in Table  2, showing a sig-
nificantly longer diabetes duration, higher SCP level and 
lower BMI at entry into the study in the gluten-free diet 
cohort.
The differences in dietary intake show that the younger 
children (aged six to nine) obtained 29 % of their energy 
from carbohydrates, compared to 52 % in their apparently 
healthy counterparts from the national dietary survey. 
For the older group of children (aged 11–13) the energy 
contribution from carbohydrates was 43 %, compared to 
53 % in their apparently healthy counterparts. There was 
no correlation between the percentage of energy from 
carbohydrates and HbA1c (r = 0.06; p = 0.87). There was 
a significant negative association between the daily exog-
enous insulin dose per kg and the percentage of energy 
from carbohydrates (r = −0.70; p = 0.02). Six out of 14 
indicated adherence below 100  %, one never answered 
this question.
HbA1c was significantly lower in the children on 
the gluten-free diet compared to both the Danish 
[−12.5 mmol/mol(CI 95 % −18.6; −6.3 mmol/mol)] and 
European cohorts [−12.3  mmol/mol (CI 95  % −18.3; 
−6.3 mmol/mol)] (p < 0.001), which corresponds to more 
than 20 % reduction in HbA1c. The same was found for 
IDAA1c, which was significantly lower in children on 
gluten-free diet than both the Danish-1.13 (CI 95  % 
−1.95; −0.32) and European cohorts −1.16 (CI 95  % 
−1.95; −0.37) (p < 0.01) (Fig. 1).
When log SCP was compared between the cohorts the 
estimated log (C-peptide) was 1.31 (CI 95  % 0.87; 1.99) 
(p = 0.20) times that of the gluten-free diet group in the 
Danish cohort; whereas the estimated log (C-peptide) 
in the European cohort was 0.88 (CI 95  % 0.59; 1.32) 
(p  =  0.54) compared to the intervention group when 
adjusted for stimulated blood glucose. The Danish cohort 
was stimulated with a mixed meal containing more car-
bohydrate and less protein. The stimulated blood glucose 
was [2.7 mmol/L (CI 95 % 0.7; 4.7 mmol/L)] higher than 
the gluten-free (Fig. 1). The blood glucose was indifferent 
in the gluten-free diet cohort and the European cohort 
[−0.4  mmol/L (CI 95  % −2.4; 1.5  mmol/L)] where the 
same boost was used. The insulin dose per day was the 
same in all three cohorts (p > 0.05). The PR according to 
the different definitions is outlined in Table 3.
There was no significant difference according to 
injection method in the gluten-free cohort (p  =  0.52), 
where those on insulin pumps had a mean HbA1c of 
53.4 mmol/mol whereas, those on pens had a mean value 
of 51.4 mmol/mol.
After 6 months significantly more children were in PR 
defined by IDAA1c in the gluten-free diet cohort com-
pared to the European cohort; whereas there was no 
difference between the gluten-free diet cohort and the 
Danish cohort. After 12  months three times as many 
children were in PR defined by IDAA1c in the gluten-free 
diet cohort compared to both the European and Danish 
cohort.
An intention to treat analysis was performed includ-
ing data from the child who never started out on gluten-
free diet and the overall results were the same—data not 
shown.
Discussion
A gluten-free diet at diabetes onset is associated with 
improved HbA1c and three times as many subjects in 
PR (defined by IDAA1c) after 12  months. Families are 
interested in the gluten-free diet just after onset of T1D 
if the diet is likely to prolong remission and improve out-
come. However, 100 % adherence to the diet is difficult to 
obtain.
To detect a 50 % reduction of the rate of decline in SCP, 
approximately 30 individuals are needed. Therefore, this 
study is underpowered to test a change of this magni-
tude. The overall tendency is a similar rate of decline in 
SCP in the three cohorts. Perhaps the results presented 
reflect improved insulin sensitivity in the gluten-free 
intervention. A gluten-free diet in pre-diabetes individu-
als led to a lower insulin resistance (HOMA-IR index), 
which increased when they returned to their normal 
diet (Pastore et  al. 2003). If a gluten-free diet improves 
insulin sensitivity then the same amount of boost (6 ml/
Table 2 Unadjusted comparison of  the three cohorts regarding  gender, age, BMI z-score and  SCP at  inclusion, as  well 
as the duration of diabetes when BMI and SCP were evaluated
Variable Danish European Gluten-free p value
Gender (M/F) 66/63 128/133 11/4 0.19
Age at onset in years (mean/SD) 10.0 (± 0.3) 9.1 (± 0.2) 9.1 (± 1.1) 0.06
z-BMI (mean/SD) 0.43 (0.1) 0.40 (± 0.1) −0.1 (± 0.3) 0.30
C-peptide at inclusion pmol/L (median/range) 629 (10–1934) 409 (10–2040) 566 (57–1360) <0.01
Duration at first visit in years (mean/SD) 0.09 (0.00) 0.10 (0.01) 0.21 (0.04) <0.01
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kg) during the observation period may give rise to lower 
postprandial glucose levels and stimulate beta cells less, 
thereby introducing a false lower C-peptide response.
The lower IDAA1c is due to the lower HbA1c since 
insulin dosing were the same, indicating the need for 
less insulin to reach the same HbA1c. Several benefi-
cial effects of a gluten-free diet may explain the positive 
results regarding HbA1c and IDAA1c in the interven-
tion group. Gluten (consisting of gliadin and glutenins) in 
the diet is known to increase gut permeability and T1D 
patients have increased gut permeability in comparison 
to healthy subjects (Bosi et  al. 2006). Increased perme-
ability allows macromolecules to pass from the gut to the 
bloodstream and may interfere with the inflammatory 
Fig. 1 The differences between the gluten-free diet and the two previous cohorts at inclusion, after six months and 12 months. a Log(SCP) 
p = 0.0016 for differences between cohorts, and p = 0.36 for differences between intervention and the Danish cohort and p = 0.45 for the differ-
ence between intervention and European cohort. b Stimulated blood glucose; the test for overall difference was <0.0001, the p value for the dif-
ference between intervention and Danish cohort was p = 0.003, and for the difference between the intervention and European p = 0.81. c HbA1c 
(IFCC) in mmol/mol—the p < 0.01 for both the tested difference for Danish and intervention and European and intervention. d IDAA1c with similar 
results (p < 0.01)
Table 3 PR after 6 and 12 months adjusted for BG stimulated
Variable Danish European Gluten-free p value G versus D p value G versus I
6 Months
PR IDAA1c (≤9) 56/118 (51.6 %) 104/235 (44.3 %) 11/15 (73.3 %) 0.51 0.01
PR SCP (>300 pmol/L) 83/117 (70.9 %) 114/237 (48.1 %) 10/14 (71.4 %) 0.55 0.08
12 Months
PR IDAA1C (≤9) 23/119 (19.3 %) 41/233 (17.6 %) 7/13 (53.8 %) 0.02 <0.001
PR SCP (>300 pmol/L) 57/120 (47.5 %) 71/240 (29.6 %) 4/13 (30.8 %) 0.10 0.83
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system, e.g. change the Th1/Th2 balance towards a more 
anti-inflammatory immune reaction and increase NK-
cell activity (Drago et  al. 2006; Ejsing-Duun et  al. 2008; 
Antvorskov et al. 2013; Larsen et al. 2014). Besides this, 
gluten-free diet changes the intestinal flora (Marietta 
et al. 2013). Of special interest is the fact that Akkerman-
sia mucinophilic bacteria increase in number. They eat 
the mucus layer in the intestine, giving rise to increased 
mucin synthesis and tight junctions, leading to better 
gut integrity. They have also been associated with diabe-
tes protection (Hansen et al. 2012). Recently it has been 
shown that uptake of/absorbed gliadin fragments are 
transported to the pancreas, where they increase insulin 
secretion and thereby exhaust the beta cells (Dall et  al. 
2013).
The low carbohydrate intake in the intervention 
group in comparison to healthy school children and 
probably the two previous cohorts could explain lower 
IDAA1c levels (Arora and McFarlane 2005; Rovner 
et al. 2009). Though, we could not confirm an associa-
tion between carbohydrate in the diet and HbA1c, and 
the association between insulin dose and carbohy-
drate in the diet is the opposite of what was expected. 
These results speak against explaining the difference in 
IDDA1c by carbohydrate content. In general, children 
with diabetes tend to eat healthier than the general 
population (Due et  al. 2013). The gluten-free cohort 
had lower HbA1c and relatively higher SCP at inclu-
sion; this could be due to the timing of first C-peptide 
measure since SCP after onset seems to peak around 
3 months after onset. Another limitation is the cohorts 
represent different treatment periods. This could, how-
ever, lead to an under-estimated effect of gluten-free 
diet as individuals studied more recently had a faster 
rate of decline of C-peptide over time when compared 
to older cohorts of children with T1D (Max Andersen 
et  al. 2014a). None in the two previous cohorts were 
using insulin pumps. In the older cohorts there may 
be factors influencing the insulin dosing such as use of 
insulin analogs and treatment target may have changed. 
On the other hand, the HbA1c levels was similar in 
those on pumps and pens, indicating that type of injec-
tion method could not explain the better HbA1c. Fur-
thermore, HbA1c levels has not decreased significantly 
in the Danish population from 2005 until 2012 despite 
increased use of intensive treatment (Sildorf et  al. 
2016).
The strength of this study is the comprehensive inves-
tigation of these patients, including information on diet 
adherence and diet composition. The results call for 
further research into a gluten-free diet, since a gluten-
free diet has no adverse effects except for the inconven-
ience associated with avoiding gluten. Even if the effect 
is modest, studies show that even a limited amount of 
endogenous C-peptide improves acute and long-term 
complications (Steffes et al. 2003; Lachin et al. 2014). In 
two cases insulin was given prior to boost test which may 
have led to a lower level of SCP and subsequent under-
estimation of the effect of gluten-free diet. Additional it is 
a drawback that assays for C-peptide measures may have 
changed from the historical cohorts. Other limitations of 
the study include the small sample size and the non-ran-
domised design.
Intervention studies in children that are aimed to pre-
serve beta-cell function are important since children 
are more likely to experience a beneficial effect due to a 
higher degree of beta-cell replication compared to adults 
(Meier et  al. 2008). Furthermore, diet intervention is a 
multifactorial approach because gluten may affect not 
only the immune system and the gut microbiota, but may 
also have local effects in the pancreas. An advantage of 
intervention at onset is that there is no over-treatment of 
children not at risk of T1D.
The increased burden placed on the families by intro-
ducing an extra dietary intervention beside the diabetes 
diet has to be balanced, since even psychological stress 
has been shown to affect the immune system (Carlsson 
et al. 2014). Any attempts to start children on a gluten-
free diet at disease onset should be accompanied by a 
discussion of the extra burden and a careful evaluation of 
the family’s ability to cope with the diet without stress. 
On the other hand, some families may experience posi-
tive feelings when they actively do something to fight the 
C-peptide decline.
Conclusion
Gluten-free diet is feasible and, in this study, shows better 
metabolic control as assessed by HbA1c and IDAA1c and 
three times higher prevalence of PR 1 year after diagno-
sis, which is likely to improve long-term outcome (Cleary 
et al. 2001; Olsen et al. 2004). This results needs further 
confirmation as it is based on a with older cohorts with a 
less pronounced rate of decline in SCP. The true effect of 
a gluten-free diet on the immune system in humans and 
the natural course of SCP decline needs to be addressed 
in a randomized control trial.
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